Screening Protocol for Subjects Being Evaluated for Hematology Branch Protocols
This protocol is designed for screening of subjects before a decision can be made as to
their eligibility for one of the active Hematology Branch research protocols. Its purpose
is to allow detailed investigation into the hematologic or oncologic problems of these
subjects, and the status of other organ systems that would determine their ability to safely
tolerate specific aspects of active research protocols. It allows investigation as to
whether a donor is HLA matched, fit to receive G-CSF, and fit to undergo apheresis and
therefore eligible to participate as a donor on a bone marrow transplant protocol. It also
allows the investigation as to whether subjects are eligible for participation as normal
volunteer based on protocol eligibility criteria that requires generally good health status
by history or physical exam findings, or laboratory assessments. After completion of this
screening process, the subject will either be offered a chance to participate in an active
research protocol, or if no appropriate protocol is identified, subjects with hematologic or
oncologic disease will have recommendations for other treatment options relayed to the
primary or referring physician.
Primary objective is to determine subject eligibility for participation on Hematology Branch
tissue procurement or investigative therapy protocols.
Primary endpoint is the results of clinical, imaging and laboratory assessments.
Observational
N/A
Cynthia E Dunbar, M.D.
Principal Investigator
National Heart, Lung, and Blood Institute (NHLBI)
United States: Federal Government
970041
NCT00001620
December 1996
Name | Location |
---|---|
National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda, Maryland 20892 |